Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Companion Diagnostics and Cancer Biomarkers

Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation

Yu Wang, Qi Yu, Xin He, Todd Romigh, Jessica Altemus and Charis Eng
Yu Wang
1Genomic Medicine Institute; 2Taussig Cancer Institute; 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; 4Department of Genetics and Genome Sciences; and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qi Yu
1Genomic Medicine Institute; 2Taussig Cancer Institute; 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; 4Department of Genetics and Genome Sciences; and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xin He
1Genomic Medicine Institute; 2Taussig Cancer Institute; 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; 4Department of Genetics and Genome Sciences; and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Todd Romigh
1Genomic Medicine Institute; 2Taussig Cancer Institute; 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; 4Department of Genetics and Genome Sciences; and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Altemus
1Genomic Medicine Institute; 2Taussig Cancer Institute; 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; 4Department of Genetics and Genome Sciences; and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charis Eng
1Genomic Medicine Institute; 2Taussig Cancer Institute; 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; 4Department of Genetics and Genome Sciences; and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
1Genomic Medicine Institute; 2Taussig Cancer Institute; 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; 4Department of Genetics and Genome Sciences; and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
1Genomic Medicine Institute; 2Taussig Cancer Institute; 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; 4Department of Genetics and Genome Sciences; and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
1Genomic Medicine Institute; 2Taussig Cancer Institute; 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; 4Department of Genetics and Genome Sciences; and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
1Genomic Medicine Institute; 2Taussig Cancer Institute; 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; 4Department of Genetics and Genome Sciences; and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-13-0655 Published February 2014
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: December 2013 to January 2021

AbstractFull-text HTMLPDF
Total193628272026

Cited By

Article Information

Volume 13, Issue 2, pp. 517-527

DOI 
https://doi.org/10.1158/1535-7163.MCT-13-0655
PubMed 
24356815

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • Received August 9, 2013
  • Revision received December 2, 2013
  • Accepted December 11, 2013
  • Published first December 19, 2013.

Article Versions

  • Previous version (December 19, 2013 - 12:48).
  • Previous version (January 28, 2014 - 14:55).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2013 American Association for Cancer Research.

Author Information

  1. Yu Wang1,
  2. Qi Yu1,
  3. Xin He1,
  4. Todd Romigh1,
  5. Jessica Altemus1, and
  6. Charis Eng1,2,3,4,5
  1. Authors' Affiliations: 1Genomic Medicine Institute; 2Taussig Cancer Institute; 3Stanley Shalom Zielony Institute for Nursing Excellence, Cleveland Clinic; 4Department of Genetics and Genome Sciences; and 5CASE Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio
  1. Corresponding Author:
    Charis Eng, Cleveland Clinic, 9500 Euclid Avenue, NE-50, Cleveland, OH 44195. Phone: 216-444-3440; Fax: 216-636-0655; E-mail: engc{at}ccf.org
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 13 (2)
February 2014
Volume 13, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation
Yu Wang, Qi Yu, Xin He, Todd Romigh, Jessica Altemus and Charis Eng
Mol Cancer Ther February 1 2014 (13) (2) 517-527; DOI: 10.1158/1535-7163.MCT-13-0655

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation
Yu Wang, Qi Yu, Xin He, Todd Romigh, Jessica Altemus and Charis Eng
Mol Cancer Ther February 1 2014 (13) (2) 517-527; DOI: 10.1158/1535-7163.MCT-13-0655
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Plasma Metabolites Predict Response to MEK Inhibitor
  • Targets of Combined mTOR/HDAC Inhibition
  • RAS and BRAF genotyping for Anti-EGFR treatment in mCRC
Show more Companion Diagnostics and Cancer Biomarkers
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement